Publicaciones en colaboración con investigadores/as de Hospital Carlos III (110)

2020

  1. Coronavirus and other airborne agents with pandemic potential

    Current Opinion in Environmental Science and Health, Vol. 17, pp. 41-48

  2. Long-acting antiretroviral therapy

    Nature Materials, Vol. 19, Núm. 8, pp. 826-827

2015

  1. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients

    Antiviral Therapy, Vol. 20, Núm. 3, pp. 329-334

  2. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C

    Antiviral Therapy, Vol. 20, Núm. 1, pp. 65-72

  3. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  4. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy

    Journal of Viral Hepatitis, Vol. 21, Núm. 7, pp. 475-479

  2. Dolutegravir, abacavir and lamivudine as HIV therapy

    Expert Opinion on Pharmacotherapy, Vol. 15, Núm. 7, pp. 1051-1057

  3. Efficacy of prolonged tenofovir therapy on Hepatitis delta in HIV-infected patients

    AIDS, Vol. 28, Núm. 16, pp. 2389-2394

  4. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  5. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

  6. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients

    Clinical Infectious Diseases, Vol. 58, Núm. 11, pp. 1549-1553

  7. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy

    Antiviral Therapy, Vol. 19, Núm. 3, pp. 287-292

  8. Management and treatment of chronic hepatitis B in HIV-positive patients

    Annals of Medicine, Vol. 46, Núm. 5, pp. 290-296

  9. Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in Spain

    AIDS Research and Human Retroviruses, Vol. 30, Núm. 9, pp. 856-862

  10. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  11. Pharmacogenetics of antiretroviral therapy

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Núm. 8, pp. 1119-1130

  12. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies

    Antiviral Therapy, Vol. 19, Núm. 8, pp. 799-803

  13. Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy

    AIDS, Vol. 28, Núm. 10, pp. 1473-1478

  14. Towards hepatitis C eradication from the HIV-infected population

    Antiviral Research